Neurometa Therapeutics ApS: Financial statements 2025
CVR: 44557703
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Neurometa Therapeutics ApS (CVR 44557703) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -17,476 and a net result of DKK -18,563 compared with DKK -285,786 the year before. Equity in the 2025 report amounted to DKK -264,349.
- Gross Profit
- DKK -17,476
- Profit/Loss
- DKK -18,563
- Equity
- DKK -264,349
- Total Assets
- DKK 57,315
- Employees
- 0
Official annual report
How creditworthy is Neurometa Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Neurometa Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -32,077, and the net result was DKK -285,786.
About Neurometa Therapeutics ApS
Neurometa Therapeutics ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Geysir Therapeutics ApS. The management consists of Josephus Dirk Vestergaard Nieland, Preben Bruun-Nyzell and Steinunn Sara Helgudóttir. The company is owned by Neurometa Therapeutics AB. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK -17,476 and a net result of DKK -18,563 compared with DKK -285,786 the year before. Equity in the 2025 report amounted to DKK -264,349.